{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:46:32Z","timestamp":1791013592722,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1996,7]]},"DOI":"10.1212\/wnl.47.1.115","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:21:25Z","timestamp":1336915285000},"page":"115-118","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":118,"title":["Motor neuropathy due to docetaxel and paclitaxel"],"prefix":"10.1212","volume":"47","author":[{"given":"Ronnie J.","family":"Freilich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casilda","family":"Balmaceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","first-page":"2","volume":"111","year":"1989","unstructured":"McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279.","journal-title":"Ann Intern Med"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.1.1"},{"key":"e_1_3_1_4_2","first-page":"3","volume":"85","year":"1993","unstructured":"Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merabarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-394.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_1_5_2","first-page":"1","volume":"15","year":"1993","unstructured":"Forastiere AA, Neuberg D, Taylor SG, De Conti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. Monogr Natl Cancer Inst 1993;15:181-184.","journal-title":"Monogr Natl Cancer Inst"},{"key":"e_1_3_1_6_2","first-page":"3","volume":"85","year":"1993","unstructured":"Murphy WK, Fosella FV, Winn RJ, et al. Phase II study of Taxol (NSC 125973) in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-388.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.1"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.1.1"},{"key":"e_1_3_1_9_2","first-page":"2","volume":"12","year":"1994","unstructured":"Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-2308.","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_10_2","first-page":"8","volume":"25","year":"1984","unstructured":"Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984;25:83-125.","journal-title":"Pharmacol Ther"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(93)90023-K"},{"key":"e_1_3_1_12_2","first-page":"2","volume":"11","year":"1993","unstructured":"Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993;11:2010-2020.","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_13_2","first-page":"2","volume":"12","year":"1994","unstructured":"Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colonystimulating factor in patients with advanced cancer. J Clin Oncol 1994;12:241-248.","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.1"},{"key":"e_1_3_1_15_2","first-page":"4","volume":"85","year":"1993","unstructured":"Sarosy G, Reed E. Taxol dose intensification and its clinical implications. J Natl Med Assoc 1993;85:427-431.","journal-title":"J Natl Med Assoc"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350103"},{"key":"e_1_3_1_17_2","first-page":"3","volume":"39","year":"1989","unstructured":"Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-373.","journal-title":"Neurology"},{"key":"e_1_3_1_18_2","first-page":"5","volume":"53","year":"1993","unstructured":"Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53:523-527.","journal-title":"Cancer Res"},{"key":"e_1_3_1_19_2","first-page":"9","volume":"11","year":"1993","unstructured":"Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-958.","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_20_2","first-page":"2","volume":"32","year":"1991","unstructured":"Extra JM, Rousseau F, Bourhis J, Dieras V, Marty M. Phase I trial of Taxotere (RP 56976, NSC 628503) [abstract]. Proc Am Assoc Cancer Res 1991;32:205.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.1"},{"key":"e_1_3_1_22_2","first-page":"6","volume":"12","year":"1993","unstructured":"Trudeau ME, Eisenhauer E, Lofters W, et al. Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study [abstract]. Proc Am Soc Clin Oncol 1993;12:64.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410340103"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.1"},{"key":"e_1_3_1_25_2","first-page":"2","volume":"47","year":"1987","unstructured":"Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 1987;47:2486-2493.","journal-title":"Cancer Res"},{"key":"e_1_3_1_26_2","first-page":"7","volume":"51","year":"1994","unstructured":"Shahenk Z, Barohn RJ, New PZ, Mendell JR. Taxol neuropathy: electrodiagnostic and sural nerve findings. Arch Neurol 1994;51:726-729.","journal-title":"Arch Neurol"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.47.1.115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:23:43Z","timestamp":1711535023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.47.1.115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1996,7]]}},"alternative-id":["10.1212\/WNL.47.1.115"],"URL":"https:\/\/doi.org\/10.1212\/wnl.47.1.115","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,7]]}}}